To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
Farrukh T Awan
MD, MS, MBA
Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program
Nurse
Robin Klebig
MSN, APRN, CNP, AOCNP
Mayo Clinic, Rochester, Minnesota
Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology
Nurse
Mollie Moran
APRN-CNP, AOCNP
The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio
Nurse Practitioner
Moderator
Brad S Kahl
MD
Washington University School of Medicine, St Louis, Missouri
Professor of Medicine
Siteman Cancer Center, St Louis, Missouri
Director, Lymphoma Program
TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NHL and CLL.
DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for NHL and CLL in order to educate, counsel and assist patients and their families in decision-making.
At the end of the activity, learners will also be able to
- Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
- Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
- Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
- Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
- Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
- Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
- Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
- Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with and the potential role of this strategy for patients with newly diagnosed CLL.
- Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
- Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.
ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
CREDIT DESIGNATION STATEMENT
This educational activity for 2 contact hours is provided by RTP during the period of July 16, 2026, to July 16, 2027.
This activity is awarded 2 ANCC pharmacotherapeutic contact hours.
ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Awan has consulting agreements with AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; has contracted research with Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company;andis on data and safety monitoring boards/committees for Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.
MODERATOR
Dr Kahl is on advisory committees with AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; has contracted research withBeOne, Roche Laboratories Inc; and is on data and safety monitoring boards/committees for BeOne, Bristol Myers Squibb, Roche Laboratories Inc.
All of the relevant financial relationships above have been mitigated.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.
Release date: July 2026
Expiration date: July 2027
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.